Bortezomib (BTZ) is a first-in-class proteasome inhibitor approved for the therapy of multiple myeloma that also displays unique regulatory activities on immune cells. The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme exerting potent immunoregulatory effects when expressed in dendritic cells (DCs), the most potent antigen-presenting cells capable of promoting either immunity or tolerance. We previously demonstrated that, in inflammatory conditions, IDO1 is subjected to proteasomal degradation in DCs, turning these cells from immunoregulatory to immunostimulatory. In non-obese diabetic (NOD) mice, an experimental model of autoimmune diabetes, we also identified an IDO1 defect such that the DCs do not develop tolerance toward pancreatic islet autoantigens. We found that BTZ rescues IDO1 protein expression in vitro in a particular subset of DCs, i.e., plasmacytoid DCs (pDCs) from NOD mice. When administered in vivo to prediabetic mice, the drug prevented diabetes onset through IDO1- and pDC-dependent mechanisms. Although the drug showed no therapeutic activity when administered alone to overtly diabetic mice, its combination with otherwise suboptimal dosages of autoimmune-preventive anti-CD3 antibody resulted in disease reversal in 70% diabetic mice, a therapeutic effect similar to that afforded by full-dosage anti-CD3. Thus, our data indicate a potential for BTZ in the immunotherapy of autoimmune diabetes and further underline the importance of IDO1-mediated immune regulation in such disease.

The proteasome inhibitor bortezomib controls indoleamine 2,3-dioxygenase 1 breakdown and restores immune regulation in autoimmune diabetes / Mondanelli, Giada; Albini, Elisa; Pallotta, Maria T.; Volpi, Claudia; Chatenoud, Lucienne; Kuhn, Chantal; Fallarino, Francesca; Matino, Davide; Belladonna, Maria L.; Bianchi, Roberta; Vacca, Carmine; Bicciato, Silvio; Boon, Louis; Ricci, Giovanni; Grohmann, Ursula; Puccetti, Paolo; Orabona, Ciriana. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 8:APR(2017), pp. 428-440. [10.3389/fimmu.2017.00428]

The proteasome inhibitor bortezomib controls indoleamine 2,3-dioxygenase 1 breakdown and restores immune regulation in autoimmune diabetes

BICCIATO, Silvio;
2017

Abstract

Bortezomib (BTZ) is a first-in-class proteasome inhibitor approved for the therapy of multiple myeloma that also displays unique regulatory activities on immune cells. The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme exerting potent immunoregulatory effects when expressed in dendritic cells (DCs), the most potent antigen-presenting cells capable of promoting either immunity or tolerance. We previously demonstrated that, in inflammatory conditions, IDO1 is subjected to proteasomal degradation in DCs, turning these cells from immunoregulatory to immunostimulatory. In non-obese diabetic (NOD) mice, an experimental model of autoimmune diabetes, we also identified an IDO1 defect such that the DCs do not develop tolerance toward pancreatic islet autoantigens. We found that BTZ rescues IDO1 protein expression in vitro in a particular subset of DCs, i.e., plasmacytoid DCs (pDCs) from NOD mice. When administered in vivo to prediabetic mice, the drug prevented diabetes onset through IDO1- and pDC-dependent mechanisms. Although the drug showed no therapeutic activity when administered alone to overtly diabetic mice, its combination with otherwise suboptimal dosages of autoimmune-preventive anti-CD3 antibody resulted in disease reversal in 70% diabetic mice, a therapeutic effect similar to that afforded by full-dosage anti-CD3. Thus, our data indicate a potential for BTZ in the immunotherapy of autoimmune diabetes and further underline the importance of IDO1-mediated immune regulation in such disease.
2017
8
APR
428
440
The proteasome inhibitor bortezomib controls indoleamine 2,3-dioxygenase 1 breakdown and restores immune regulation in autoimmune diabetes / Mondanelli, Giada; Albini, Elisa; Pallotta, Maria T.; Volpi, Claudia; Chatenoud, Lucienne; Kuhn, Chantal; Fallarino, Francesca; Matino, Davide; Belladonna, Maria L.; Bianchi, Roberta; Vacca, Carmine; Bicciato, Silvio; Boon, Louis; Ricci, Giovanni; Grohmann, Ursula; Puccetti, Paolo; Orabona, Ciriana. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 8:APR(2017), pp. 428-440. [10.3389/fimmu.2017.00428]
Mondanelli, Giada; Albini, Elisa; Pallotta, Maria T.; Volpi, Claudia; Chatenoud, Lucienne; Kuhn, Chantal; Fallarino, Francesca; Matino, Davide; Bellad...espandi
File in questo prodotto:
File Dimensione Formato  
Mondanelli_et_al_2017_FontImmm.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 2.77 MB
Formato Adobe PDF
2.77 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1134650
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 28
social impact